48 related articles for article (PubMed ID: 9205093)
1. Correspondence re: C.V. Rao, et al., Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced lymphoma formation by oltipraz. Cancer Res., 56: 3395-3398, 1996.
Roebuck BD; Rogers AE; Kensler TW
Cancer Res; 1997 Jul; 57(13):2806-7. PubMed ID: 9205093
[No Abstract] [Full Text] [Related]
2. Inhibition of 2-Amino-1-methyl-6-phenylimidazo[4,5]pyridine-induced lymphoma formation by oltipraz.
Rao CV; Rivenson A; Zang E; Steele V; Kelloff G; Reddy BS
Cancer Res; 1996 Aug; 56(15):3395-8. PubMed ID: 8758900
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer.
Kensler TW; Gange SJ; Egner PA; Dolan PM; Muñoz A; Groopman JD; Rogers AE; Roebuck BD
Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):603-10. PubMed ID: 9264273
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz.
Roebuck BD; Curphey TJ; Li Y; Baumgartner KJ; Bodreddigari S; Yan J; Gange SJ; Kensler TW; Sutter TR
Carcinogenesis; 2003 Dec; 24(12):1919-28. PubMed ID: 14555609
[TBL] [Abstract][Full Text] [Related]
5. Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz.
Egner PA; Gange SJ; Dolan PM; Groopman JD; Muñoz A; Kensler TW
Carcinogenesis; 1995 Aug; 16(8):1769-73. PubMed ID: 7634402
[TBL] [Abstract][Full Text] [Related]
6. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.
Yates MS; Kwak MK; Egner PA; Groopman JD; Bodreddigari S; Sutter TR; Baumgartner KJ; Roebuck BD; Liby KT; Yore MM; Honda T; Gribble GW; Sporn MB; Kensler TW
Cancer Res; 2006 Feb; 66(4):2488-94. PubMed ID: 16489057
[TBL] [Abstract][Full Text] [Related]
7. Identification of dithiolethiones with better chemopreventive properties than oltipraz.
Maxuitenko YY; Libby AH; Joyner HH; Curphey TJ; MacMillan DL; Kensler TW; Roebuck BD
Carcinogenesis; 1998 Sep; 19(9):1609-15. PubMed ID: 9771932
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of the oxidized metabolites of oltipraz on the activation of CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 for GSTA2 gene induction.
Ko MS; Lee SJ; Kim JW; Lim JW; Kim SG
Drug Metab Dispos; 2006 Aug; 34(8):1353-60. PubMed ID: 16714377
[TBL] [Abstract][Full Text] [Related]
9. Development of cancer chemopreventive agents: oltipraz as a paradigm.
Kensler TW; Groopman JD; Sutter TR; Curphey TJ; Roebuck BD
Chem Res Toxicol; 1999 Feb; 12(2):113-26. PubMed ID: 10027787
[No Abstract] [Full Text] [Related]
10. Sex-specific induction of mutations by PhIP in the kidney of male and female rats and its modulation by conjugated linoleic acid.
Yang H; Glickman BW; de Boer JG
Environ Mol Mutagen; 2002; 40(2):116-21. PubMed ID: 12203404
[TBL] [Abstract][Full Text] [Related]
11. Modulation of aflatoxin toxicity and biomarkers by lycopene in F344 rats.
Tang L; Guan H; Ding X; Wang JS
Toxicol Appl Pharmacol; 2007 Feb; 219(1):10-7. PubMed ID: 17229449
[TBL] [Abstract][Full Text] [Related]
12. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers.
Kensler TW; He X; Otieno M; Egner PA; Jacobson LP; Chen B; Wang JS; Zhu YR; Zhang BC; Wang JB; Wu Y; Zhang QN; Qian GS; Kuang SY; Fang X; Li YF; Yu LY; Prochaska HJ; Davidson NE; Gordon GB; Gorman MB; Zarba A; Enger C; Muñoz A; Helzlsouer KJ
Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):127-34. PubMed ID: 9488587
[TBL] [Abstract][Full Text] [Related]
13. Prostate mutations in rats induced by the suspected human carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Stuart GR; Holcroft J; de Boer JG; Glickman BW
Cancer Res; 2000 Jan; 60(2):266-8. PubMed ID: 10667573
[TBL] [Abstract][Full Text] [Related]
14. [Studies on inhibition of human lung carcinogenesis in early stage by oltipraz and its effects on some gene expression and regulation].
Bai H
Sheng Li Ke Xue Jin Zhan; 1998 Jul; 29(3):235-8. PubMed ID: 12501642
[TBL] [Abstract][Full Text] [Related]
15. N-acetyltransferase-dependent activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine: formation of 2-amino-1-methyl-6-(5-hydroxy)phenylimidazo [4,5-b]pyridine, a possible biomarker for the reactive dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Frandsen H; Alexander J
Carcinogenesis; 2000 Jun; 21(6):1197-203. PubMed ID: 10837010
[TBL] [Abstract][Full Text] [Related]
16. Animal models and analytical approaches for understanding the relationships between wine and cancer.
Ebeler SE; Dingley KH; Ubick E; Abel S; Mitchell AE; Burns SA; Steinberg FM; Clifford AJ
Drugs Exp Clin Res; 2005; 31(1):19-27. PubMed ID: 15921026
[TBL] [Abstract][Full Text] [Related]
17. Clinical development plan: oltipraz.
Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
J Cell Biochem Suppl; 1994; 20():205-18. PubMed ID: 7616744
[No Abstract] [Full Text] [Related]
18. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine induces a higher number of aberrant crypt foci in Fischer 344 (rapid) than in Wistar Kyoto (slow) acetylator inbred rats.
Purewal M; Velasco M; Fretland AJ; Hein DW; Wargovich MJ
Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):529-32. PubMed ID: 10815700
[TBL] [Abstract][Full Text] [Related]
19. [Studies on apoptosis of human lung adenocarcinoma cells induced by oltipraz].
Bai H; Luo X; Hu G; Wei H; Chen F; Zhu M
Zhonghua Yu Fang Yi Xue Za Zhi; 1999 May; 33(3):152-5. PubMed ID: 11864473
[TBL] [Abstract][Full Text] [Related]
20. Effects of bile acids on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced aberrant crypt foci and DNA adduct formation in the rat colon.
Ueyama Y; Monden Y; He XB; Lin CX; Momen MA; Mimura S; Umemoto A
J Exp Clin Cancer Res; 2002 Dec; 21(4):577-83. PubMed ID: 12636105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
